Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. METHODS: A phase 1 clinical trial was...

Descripción completa

Detalles Bibliográficos
Autores principales: Vonderheide, Robert H, Kraynyak, Kimberly A, Shields, Anthony F, McRee, Autumn J, Johnson, Jennifer M, Sun, Weijing, Chintakuntlawar, Ashish V, Pawlicki, Jan, Sylvester, Albert J, McMullan, Trevor, Samuels, Robert, Kim, Joseph J, Weiner, David, Boyer, Jean D, Morrow, Matthew P, Humeau, Laurent, Skolnik, Jeffrey M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261871/
https://www.ncbi.nlm.nih.gov/pubmed/34230114
http://dx.doi.org/10.1136/jitc-2021-003019

Ejemplares similares

Ejemplares similares